Pelthos Therapeutics Inc. SEC filings PTHS
Pelthos Therapeutics Inc. has 253 filings in SEC EDGAR's recent list, going back to Sep 6, 2022. Its latest annual report, Form ARS, was filed on Aug 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (material agreement, new debt, unregistered share sale, change to shareholder rights, officer or director change, bylaw or fiscal year change, shareholder vote results, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Feb 13, 2026 | — |
| S-3 | Shelf registration | Feb 2, 2026 | — |
| 424B3 | Prospectus | Sep 29, 2025 | — |
| S-3/A | Filing | Sep 19, 2025 | — |
| S-3 | Shelf registration | Aug 28, 2025 | — |
| S-8 | Employee stock plan registration | Jul 25, 2025 | — |
| POS AM | Filing | Dec 11, 2024 | — |
| POS AM | Filing | Nov 22, 2024 | — |
| POS AM | Filing | Nov 22, 2024 | — |
| 424B3 | Prospectus | Nov 13, 2024 | — |
| 424B3 | Prospectus | Nov 13, 2024 | — |
| 424B3 | Prospectus | Aug 13, 2024 | — |
| 424B3 | Prospectus | Aug 13, 2024 | — |
| 424B3 | Prospectus | Aug 6, 2024 | — |
| S-1 | Registration statement | Jul 29, 2024 | — |
| 424B3 | Prospectus | Jul 29, 2024 | — |
| 424B3 | Prospectus | Jul 29, 2024 | — |
| 424B3 | Prospectus | May 15, 2024 | — |
| 424B3 | Prospectus | May 15, 2024 | — |
| 424B3 | Prospectus | Apr 17, 2024 | — |
| 424B3 | Prospectus | Apr 17, 2024 | — |
| S-8 | Employee stock plan registration | Apr 15, 2024 | — |
| 424B4 | Prospectus | Feb 20, 2024 | — |
| 424B4 | Prospectus | Feb 20, 2024 | — |
| S-1/A | Amended registration statement | Feb 14, 2024 | — |
| FWP | Free writing prospectus | Feb 12, 2024 | — |
| S-1/A | Amended registration statement | Feb 12, 2024 | — |
| FWP | Free writing prospectus | Feb 7, 2024 | — |
| S-1/A | Amended registration statement | Feb 7, 2024 | — |
| FWP | Free writing prospectus | Jan 31, 2024 | — |
| S-1/A | Amended registration statement | Jan 30, 2024 | — |
| S-1/A | Amended registration statement | Jan 16, 2024 | — |
| FWP | Free writing prospectus | Nov 8, 2023 | — |
| S-1/A | Amended registration statement | Nov 8, 2023 | — |
| S-1/A | Amended registration statement | Oct 25, 2023 | — |
| FWP | Free writing prospectus | Oct 16, 2023 | — |
| S-1/A | Amended registration statement | Oct 16, 2023 | — |
| S-1/A | Amended registration statement | Sep 1, 2023 | — |
| S-1/A | Amended registration statement | Jul 20, 2023 | — |
| S-1/A | Amended registration statement | Jun 30, 2023 | — |
| S-1/A | Amended registration statement | May 1, 2023 | — |
| S-1/A | Amended registration statement | Jan 20, 2023 | — |
| S-1 | Registration statement | Jan 11, 2023 | — |
Showing 43 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PTHS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Durham, NC
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1919246
- Former names
- Channel Therapeutics Corp (until May 27, 2025); Chromocell Therapeutics Corp (until Nov 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.